Rocket Pharmaceuticals, Inc.
rocketpharma.comWhat Do They Do?
Develops and manufactures genetic therapies for rare, often fatal diseases, including inherited heart disorders and blood or immune conditions.
10-K for FY2025, filed Feb 26, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
$123.2MView ↗
- ▲ Now profitable
- vs −$68.9M in Q2 FY2025
-
Mar 27, 2026
FDA approves KRESLADI for severe LAD-I
The accelerated approval is for pediatric patients with severe LAD-I.
Sources
8-K, filed Mar 27, 2026
CRANBURY, N.J. – March 27, 2026 – Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated biotechnology company advancing a…View ↗
Pipeline focus
The earlier report described active gene therapy programs for Fanconi anemia and pyruvate kinase deficiency alongside heart-disease programs. The latest report prioritizes cardiovascular programs and deprioritizes those two blood-disorder programs.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026We are a clinical-stage, multi-platform biotechnology company focused on the development of first, only and best-in-class gene therapies…View ↗
Loading...
